To evaluate the usefulness of examined markers in predicting the effectiveness of pharmacological cardioversion we compared initial concentrations of OPG and TRAIL in subgroups with SR or AF in control visit. This evidence concerns the gene TNFRSF11B and atrial fibrillation.